HCV Protease

HDAC Inhibitor: Vorinostat (SAHA)

HDAC (Histone deacetylase)
## HCV Protease Inhibitors & Modulators

### Asunaprevir
(BMS-650032; BMS 650032; BMS650032)  
**Cat. No.: HY-14434**

**Bioactivity:** Asunaprevir is a potent hepatitis C virus (HCV) NS3 protease inhibitor, with the IC$_{50}$ of 0.2 nM-3.5 nM.

| Purity: | 99.27% |
| Clinical Data: | Phase 3 |
| Size: | 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg |

### Beclabuvir
(BMS-791325; BMS791325; BMS 791325)  
**Cat. No.: HY-12429**

**Bioactivity:** Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC$_{50}$ of < 28 nM.

| Purity: | 99.81% |
| Clinical Data: | Phase 3 |
| Size: | 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |

### Boceprevir
(EBP 520; SCH 503034; EBP-520; EBP520; SCH-503034; SCH 503034)  
**Cat. No.: HY-10237**

**Bioactivity:** Boceprevir is a novel, potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with $K_I$ of 14 nM in both enzyme assay and EC$_{50}$ of 350 nM in cell-based replicon assay.

| Purity: | 99.12% |
| Clinical Data: | Phase 4 |
| Size: | 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

### Clemizole (hydrochloride)
**Cat. No.: HY-30234A**

**Bioactivity:** Clemizole hydrochloride is an H1 histamine receptor antagonist, is found to substantially inhibit HCV replication. The IC$_{50}$ of Clemizole for RNA binding by NS4B is 24±1 nM, whereas its EC$_{50}$ for viral replication is 8 μM.

| Purity: | 99.7% |
| Clinical Data: | Phase 1 |
| Size: | 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

### Daclatasvir
(BMS-790052; EBP 883; BMS 790052)  
**Cat. No.: HY-10466**

**Bioactivity:** Daclatasvir is a potent HCV NS5A protein inhibitor, with mean EC$_{50}$ values of 50 and 9pM against genotype 1a and 1b replicons, respectively.

| Purity: | 99.31% |
| Clinical Data: | Phase 4 |
| Size: | 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg |

### Danoprevir
(ITMN-191; R7227; ROS190591; RG7227)  
**Cat. No.: HY-10238**

**Bioactivity:** Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC$_{50}$ of 0.2-3.5 nM. The inhibition effect on HCV genotypes 1A/1B/4/5/6 is appr 10-fold higher than 2B/3A.

| Purity: | 97.29% |
| Clinical Data: | Phase 2 |
| Size: | 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg |

### Ledipasvir
(GS-5885; GS 5885; GS5885)  
**Cat. No.: HY-15602**

**Bioactivity:** Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC$_{50}$ values of 34 pM against GT1a and 4 pM against GT1b replicon.

| Purity: | >98.0% |
| Clinical Data: | Phase 2, Phase 2b, Phase 3, Phase 3b |
| Size: | 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

### Ledipasvir (acetone)
(GS-5885 acetone; GS 5885 acetone; GS5885 acetone)  
**Cat. No.: HY-15602A**

**Bioactivity:** Ledipasvir acetone is an inhibitor of the hepatitis C virus NS5A, with EC$_{50}$ values of 34 pM against GT1a and 4 pM against GT1b replicon.

| Purity: | 99.98% |
| Clinical Data: | Phase 3 |
| Size: | 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

### Ledipasvir (D-tartrate)
(GS-5885 D-tartrate; GS 5885 D-tartrate)  
**Cat. No.: HY-15602B**

**Bioactivity:** Ledipasvir (GS5885) D-tartrate is an inhibitor of the hepatitis C virus NS5A protein, which is an experimental drug for the treatment of hepatitis C.

| Purity: | 99.73% |
| Clinical Data: | Phase 3 |
| Size: | 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |
## Ledipasvir (diacetone) (GS-5885 diacetone)

**Bioactivity:** Ledipasvir(GS5885) diacetone is an inhibitor of the hepatitis C virus NS5A protein; Ledipasvir is an experimental drug for the treatment of hepatitis C.

**Purity:** >98%

**Clinical Data:** Phase 3, Phase 3b

**Size:** 5 mg, 10 mg, 50 mg, 100 mg

---

## MK-5172 (hydrate) (Grazoprevir hydrate; MK5172 hydrate; MK 5172 hydrate)

**Bioactivity:** MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.

**Purity:** >98%

**Clinical Data:** Phase 2

**Size:** 5 mg, 10 mg, 50 mg, 100 mg

---

## MK-5172 (sodium salt) (Grazoprevir sodium salt; MK5172 sodium salt; MK 5172 sodium salt)

**Bioactivity:** MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.

**Purity:** >98%

**Clinical Data:** Phase 2

**Size:** 5 mg, 10 mg, 50 mg, 100 mg

---

## Narlaprevir (SCH 900518; SCH900518; SCH-900518)

**Bioactivity:** Narlaprevir is a potent, selective, orally bioavailable NS3 protease inhibitor(Ki=6 nM; EC90=40 nM)

**Purity:** >98%

**Clinical Data:** Phase 1, Phase 2

**Size:** 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg

---

## Ombitasvir (ABT-267; ABT267; ABT 267)

**Bioactivity:** Ombitasvir (ABT-267) is an inhibitor of HCV NS5A. ABT-267 inhibits replication of HCV subgenomic replicons in cell culture assays with EC50 values of 14 pM and 5 pM against genotype 1a-H77 and 1b-Con1, respectively.

**Purity:** 99.89%

**Clinical Data:** Phase 3

**Size:** 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg

---

## R-7128 (RG 7128; Mercicitabine; PSI 6130 disobutyrate)

**Bioactivity:** R-7128 is a nucleoside inhibitor of the HCV NS5B polymerase that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.

**Purity:** 99.34%

**Clinical Data:** Phase 2

**Size:** 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg

---

## PSI-6130 (R 1656; PSI 6130; PSI6130; R-1656)

**Bioactivity:** PSI-6130 is a potent and selective inhibitor of HCV NS5B polymerase.

**Purity:** 99.39%

**Clinical Data:**

**Size:** 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg

---

## Simeprevir (TMC435; TMC435350; TMC-435350)

**Bioactivity:** Simeprevir is a potent HCV NS3/4A protease inhibitor, and inhibits HCV replication with EC50 of 8 nM.

**Purity:** 99.98%

**Clinical Data:** Phase 3

**Size:** 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg
| **Telaprevir**  
(VX-950; VX950; VX 950)  
Cat. No.: HY-10235 | **TMC647055 (Choline salt)**  
Cat. No.: HY-15591A |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Telaprevir is a highly selective, reversible, and potent peptidomimetic inhibitor of the <strong>HCV NS3-4A protease</strong>, the steady-state inhibitory constant (K_i) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide.</td>
<td><strong>Bioactivity:</strong> TMC647055 choline salt is a cell-permeating, selective HCV NS5B inhibitor, eliciting a mean IC50 of 34 nM, as assessed in the RdRp primer-dependent transcription assay.</td>
</tr>
<tr>
<td><strong>Purity:</strong> &gt;98.0%</td>
<td><strong>Purity:</strong> 99.73%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> Phase 4</td>
<td><strong>Clinical Data:</strong> Phase 2</td>
</tr>
<tr>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</td>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

| **Vaniprevir**  
(MK-7009; MK7009; MK 7009)  
Cat. No.: HY-10243 | **VCH-916**  
(VCH916; VCH 916)  
Cat. No.: HY-13465 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.</td>
<td><strong>Bioactivity:</strong> VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.</td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.24%</td>
<td><strong>Purity:</strong> 99.51%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> Phase 2, Phase 3</td>
<td><strong>Clinical Data:</strong> Phase 4</td>
</tr>
<tr>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 5 mg, 10 mg</td>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

| **Velpatasvir**  
(GS-5816; GS 5816; GS5816)  
Cat. No.: HY-12530 | **VX-222**  
(VCH222; VX222; VCH 222; VCH-222)  
Cat. No.: HY-75800 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons.</td>
<td><strong>Bioactivity:</strong> VX-222 (VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L.</td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.71%</td>
<td><strong>Purity:</strong> &gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td><strong>Clinical Data:</strong></td>
</tr>
<tr>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</td>
<td><strong>Size:</strong> 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</td>
</tr>
</tbody>
</table>